The observed mutation rates, particularly in EGFR, underscore the potential for targeted therapies in Moroccan NSCLC patients, emphasizing the need for further research to refine treatment strategies tailored to this population. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.